US EditionPublished • loading... • Updated
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
Antengene and Junshi Biosciences begin trials in China combining CD73 inhibition with dual PD-1/VEGF targeting to enhance treatment durability and survival in solid tumors.
Summary by PR Newswire
7 Articles
7 Articles
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to...
·United States
Read Full Article
New Hamburg independent+5 Reposted by 5 other sources
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has entered into…
·New Hamburg, Canada
Read Full ArticleCoverage Details
Total News Sources7
Leaning Left4Leaning Right2Center1Last UpdatedBias Distribution57% Left
Bias Distribution
- 57% of the sources lean Left
57% Left
L 57%
14%
R 29%
Factuality
To view factuality data please Upgrade to Premium
